Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Clinical trial NCT01486446 · COMPLETED
Trial details
- NCT number
- NCT01486446
- Sponsor
- Xenon Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-12-01
- Primary completion
- 2012-04-01
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.